by Alexander Habermeier | Mar 26, 2026 | Blog
In my recent open letter to founders, “The MedTech Valley of Death”[8], I made a blunt assertion. Eliminating unforced regulatory errors to secure a 30 percent faster FDA clearance is the ultimate survival lever for an early-stage MedTech CEO. But...
by Alexander Habermeier | Mar 6, 2026 | Blog, News
By Alexander Habermeier What does building ambitious health technology look like when regulatory approval is part of the equation from day one? On February 12th, during the Guideways Launch Event in Utrecht, we gathered a group of innovators who are moving the needle...
by Alexander Habermeier | Feb 22, 2026 | Blog
By Alexander Habermeier There is a brutal reality in the current medical device ecosystem that nobody wants to talk about during pitch meetings. Out of every ten brilliantly engineered devices (devices just like yours) eight or nine are dying before reaching patients...
by admin | Jan 12, 2026 | Blog
Compliance vs. regulatory intent In highly regulated industries, there is a temptation to treat FDA guidance as a checklist. However, experienced reviewers know that regulatory intent matters more than rote compliance. The FDA’s guidance on clinical decision support...
by admin | Jan 7, 2026 | Blog
Most regulatory problems are locked in early Medical device executives often focus on the moment of submission, yet many delays stem from decisions made months or years earlier. The FDA’s average 510(k) submission now exceeds 1.000 pages, even though it is the...
by admin | Jan 2, 2026 | Blog
Why the AI hype has not solved regulatory navigation yet Large‑language models and other foundation models have made it possible to search and summarise FDA guidance at unprecedented speed. However, subject matter experts note that they do not automatically translate...